How we manage invasive fungal disease in acute myeloid leukemia patients with Glucose 6 Dehydrogenase deficiency

Main Article Content

Marco Sanna
Giovanni Caocci *
Giorgio La Nasa
(*) Corresponding Author:
Giovanni Caocci | giovanni.caocci@unica.it


Downloads month by month

Downloads

Download data is not yet available.

Article Details

References

[1]Luzzatto L, Nannelli C, Notaro R. Glucose-6-Phosphate Dehydrogenase Deficiency. Hematol Oncol Clin North Am. 2016; 30:373–93.
[2]Luzzatto L, Seneca E. G6PD deficiency: a classic example of pharmacogenetics with on-going clinical implications. Br J Haematol. 2014; 164:469–480.
[3] Spolarics Z, Siddiqi M, Siegel JH, et al. Increased incidence of sepsis and altered monocyte functions in severely injured type A- glucose-6-phosphate dehydrogenase-deficient African American trauma patients. Crit Care Med. 2001; 29:728-36.
[4]Abu-Osba YK, Mallouh AA, Hann RW. Incidence and causes of sepsis in glucose-6-phosphate dehydrogenase-deficient newborn infants. J Pediatr. 1989; 114:748-52.
[5]Meloni T, Forteleoni G, Ena F, et al. Glucose-6-phosphate dehydrogenase deficiency and bacterial infections in northern Sardinia. J Pediatr. 1991; 118:909-11.
[6]Rodey GH, Jacob HS, Holmes B, et al. Leucocyte G6PD levels and bacterial activity. Lancet, 1970; 1:355-6.
[7] Sanna M, Caocci G, Ledda A, et al. Glucose-6-Phosphate Deidhrogenase deficiency and risk of invasive fungal disease in patients with acute myeloid leukemia. Leuk Lymphoma. 2017; Epub ahead of print
[8]Domingo GJ, Satyagraha AW, Anvikar A, et al. G6PD testing in support of treatment and elimination of malaria: recommendations for evaluation of G6PD tests. Seidlein L.Malar J. 2013;12:391
[9]Lamoth F, Cruciani M, Mengoli C, et al. Third European Conference on Infections in Leukemia (ECIL-3). β-Glucan antigenemia assay for the diagnosis of invasive fungal infections in patients with hematological malignancies: a systematic review and meta-analysis of cohort studies from the Third European Conference on Infections in Leukemia (ECIL-3). Clin Infect Dis. 2012;54:633-43
[10]Pappas GP. Clinical Infectious Diseases Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious DiseasesSociety of America.Clin Infect Dis. 2016;62:e1-50.
[11]Tissot F, Agrawal S, Pagano L. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017; 102:433-444.